Why It Matters
Billions of dollars appropriated by Congress for global HIV/AIDS programs are sitting unspent, as the Trump administration restructures decades-old foreign aid systems. The funding delays are threatening to shut down life-saving HIV treatment and prevention programs across Africa — programs that even the current administration has acknowledged as essential.
The situation highlights a growing tension between congressional appropriations and executive branch spending authority, with real consequences for public health infrastructure built over more than two decades of U.S. investment.
What Happened
Congress, in fiscal year 2026, appropriated close to $6 billion for global HIV/AIDS work — funding the President’s Emergency Plan for AIDS Relief (PEPFAR) at virtually the same level as the previous fiscal year. This came after lawmakers pushed back on proposed cuts to the program in 2025.
Despite those funds being available, people inside and outside the federal government say the State Department is deliberately withholding a significant portion of the money. The result is that NGOs and health organizations operating in Africa — including programs the Trump administration itself has labeled “lifesaving” — are on the verge of shutting down critical operations.
Dr. Caspian Chouraya, who oversees HIV/AIDS programs in 12 African countries for the Elizabeth Glaser Pediatric AIDS Foundation, says funding has been arriving “in fits and starts” for months. Based in Eswatini — formerly Swaziland, where more than a quarter of adults were once infected with HIV — Chouraya now spends much of his time consulting legal advisors about layoff procedures rather than focusing on medical work.
The funding freeze comes as the Trump administration dismantles the U.S. Agency for International Development (USAID), which previously oversaw tens of billions in foreign aid, and replaces it with a new framework under the America First Global Health Strategy. That strategy directs the State Department to negotiate new aid contracts directly with recipient country governments, with shared accountability measures.
By the Numbers
$6 billion — the amount Congress appropriated for global HIV/AIDS programs in fiscal year 2026, roughly matching the prior year’s funding level.
$100 billion — the total amount the United States has committed to global HIV/AIDS work since PEPFAR launched in 2003 under President George W. Bush.
26 million lives — the number of lives PEPFAR has been credited with saving since its inception.
53 health facilities in Côte d’Ivoire alone are covered under Chouraya’s programs, which were forced to scale back training and services while waiting for delayed bridge funding that finally arrived in March.
Six months — the self-imposed deadline the State Department set to have new health aid systems operational. That deadline passed on March 31, and the transition is reportedly running behind schedule.
Zoom Out
PEPFAR, launched in 2003 under President George W. Bush, is widely regarded as one of the most successful global health initiatives in U.S. history. Its bipartisan foundation has meant consistent congressional support across administrations — until now.
The Trump administration’s approach reflects a broader philosophy of reducing Washington’s role in long-term foreign aid commitments and shifting financial responsibility to recipient nations. Jennifer Kates, senior vice president and director of Global Health and HIV Policy at KFF, notes that transitioning countries toward self-sufficiency was always a long-term goal of PEPFAR — but warns the speed and manner of the current transition carries significant risks to existing health infrastructure.
The restructuring is part of a larger pattern of executive branch spending realignment. President Trump’s fiscal year 2027 budget proposes a 43% increase in defense spending alongside deep cuts to domestic and foreign-facing programs, signaling a continued shift in federal funding priorities.
What’s Next
The State Department’s self-imposed March 31 deadline for completing its transition to new aid delivery systems has passed without full implementation. Officials have not publicly confirmed a revised timeline.
Organizations like the Elizabeth Glaser Pediatric AIDS Foundation are warning that further delays could force permanent closures of support programs, staff layoffs, and interruptions in drug delivery to patients who depend on consistent treatment. Chouraya says he has already begun preparing staff termination notices as a precaution.
Congress has so far maintained strong bipartisan support for PEPFAR funding levels, but lawmakers have limited tools to compel the executive branch to disburse appropriated funds on a set schedule. Whether Congress takes additional action to enforce its funding intentions remains to be seen.
For now, programs serving some of the most vulnerable HIV patients on the continent remain in limbo — funded on paper, but not in practice.